Cancer

Aeolus Pharmaceuticals' AEOL 10113 Demonstrates Potential to Accelerate Recovery of Bone Marrow Stem Cells Following Cancer Radiation Therapy

Published in Blood Weekly, May 10th, 2007

Aeolus Pharmaceuticals, Inc. (OTCBB:AOLS) announced the presentation of data by researchers at Loma Linda University Medical Center, National Jewish Medical and Research Center and Duke University showing that one of the Company's metalloporphyrin antioxidants, AEOL 10113, accelerates the recovery of blood cellular components derived from stem cells.

Success with cancer radiotherapy is limited by damage to normal tissues, such as the hematopoietic/immune system. AEOL 10113 was studied to determine its ability to modify radiation induced effects on bone marrow-derived cells. Researchers observed greater increases in DNA synthesis in samples of whole blood taken 4 days...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Blood Weekly

Source: Blood Weekly (2007-05-10)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry